Welcome to our dedicated page for Accolade news (Ticker: ACCD), a resource for investors and traders seeking the latest updates and insights on Accolade stock.
Accolade, Inc. (ACCD) delivers technology-powered healthcare solutions that combine virtual care with expert clinical navigation. This news hub provides investors and industry professionals with essential updates on the company’s strategic initiatives and market position.
Track official press releases, earnings announcements, and operational developments through our curated collection. Find timely information on healthcare partnerships, service expansions, and technology innovations that shape Accolade’s role in personalized care solutions.
Our repository includes updates across key business areas: financial results, leadership changes, clinical program enhancements, and regulatory milestones. Each entry is sourced directly from company communications to ensure accuracy and compliance.
Bookmark this page for streamlined access to ACCD’s evolving story in healthcare technology. Monitor how the company’s unique blend of digital tools and clinical expertise continues to redefine employer-sponsored and individual healthcare navigation.
Accolade, Inc. (Nasdaq: ACCD) has finalized its acquisition of Innovation Specialists, LLC (d/b/a 2nd.MD) for up to $460 million. This strategic move combines expertise in benefit navigation, health advocacy, and expert medical opinions, enhancing healthcare navigation for over 9 million lives across 400 customers. The transaction includes $230 million in cash and stock, with an additional $100 million contingent upon revenue milestones. This merger is expected to expand Accolade’s addressable market by $22 billion.
Accolade, Inc. (NASDAQ: ACCD) will participate in two upcoming investor conferences: the BTIG Virtual MedTech Conference on February 17, 2021, at 4:00 p.m. E.T. and the SVB Leerink Global Healthcare Conference on February 24, 2021, at 9:20 a.m. E.T. Audio webcasts and presentation materials will be available at ir.accolade.com. Accolade offers personalized health and benefits solutions, aiding users in navigating the healthcare system, achieving high consumer satisfaction ratings and lowering healthcare costs.
Accolade (Nasdaq: ACCD) has appointed Cindy R. Kent to its board of directors, effective immediately. Kent, the current executive vice president of Brookdale Senior Living and former head of 3M's Infection Prevention Division, brings extensive healthcare and business operations experience. CEO Rajeev Singh expressed that her leadership will provide valuable insights as Accolade grows. Kent's proven track record includes overseeing significant revenue operations in major healthcare sectors. Additionally, the company announced the departure of board members Michael Yang and Jim Madden.
Accolade has announced its acquisition of 2nd.MD, a leading Expert Medical Opinion company, for up to $460 million. The deal involves $230 million in cash, $130 million in stock, and up to $100 million contingent on revenue milestones. This acquisition aims to enhance Accolade's healthcare navigation services, targeting a market expansion worth $22 billion. The integration is expected to be accretive to revenue growth in fiscal 2022, with the potential for significant employer savings per consultation. The transaction is anticipated to close by February 2021.
Accolade, Inc. (NASDAQ: ACCD) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 2:50 p.m. E.T. This event will include an audio webcast and presentation materials available on their investor relations website. Accolade specializes in personalized, technology-enabled healthcare solutions that help individuals navigate the healthcare system effectively. The company aims to empower users with over 90% consumer satisfaction and a Net Promoter Score (NPS) of 60.
Accolade, Inc. (NASDAQ: ACCD) reported a fiscal third-quarter 2021 revenue of $38.4 million, reflecting a 30% increase from $29.7 million in the same quarter last year. This growth was attributed to new customer additions across various market segments. The company raised its revenue outlook for the fiscal year to $162 million to $165 million, indicating a projected growth of 22% to 25% over fiscal year 2020. Despite a net loss of $(16.6) million, down from $(18.3) million, Accolade's adjusted gross profit rose 32%.
Accolade, Inc. (NASDAQ: ACCD) will release its fiscal Q3 2021 financial results on January 7, 2021, after the market close. A conference call will follow at 4:30 p.m. ET to discuss the results. Participants can join by calling 1-833-519-1281 or via an audio webcast on Accolade's investor relations website. The company specializes in personalized health and benefits solutions, enhancing engagement through tailored support and technology. Accolade aims to lower healthcare costs while maintaining high consumer satisfaction ratings above 90% and an NPS of 60.
Accolade, Inc. (NASDAQ: ACCD) participated in the William Blair Healthcare 2021 Focus List Event on December 17, 2020. Rajeev Singh, CEO, delivered a fireside chat presentation, discussing Accolade's innovative healthcare solutions. The company specializes in personalized, technology-driven health and benefits solutions that empower individuals to navigate their healthcare systems effectively. With a remarkable NPS of 60 and consumer satisfaction rates exceeding 90%, Accolade aims to simplify healthcare for employees while reducing associated costs.
Accolade, Inc. (NASDAQ: ACCD) will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020. This event includes a fireside chat presentation. Participants can access an audio replay and related materials on ir.accolade.com. Accolade provides personalized health solutions that empower individuals to navigate the healthcare system effectively, boasting consumer satisfaction ratings over 90% and a net promoter score of 60.
FAQ
What is the current stock price of Accolade (ACCD)?
What is the market cap of Accolade (ACCD)?
